PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis

William Sandborn, Larry C. Mattheakis, Nishit B. Modi, David Pugatch, Brian Bressler, Scott Lee, Raj Bhandari, Bittoo Kanwar, Richard Shames, Geert D’Haens, Stefan Schreiber, Silvio Danese, Brian Feagan, Rish K. Pai, David Y. Liu, Suneel Gupta, Gastroenterology, August 29, 2021. View Page

Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers

Nishit B. Modi, Xiaoli Cheng, Larry Mattheakis, Ching-Chang Hwang, Roya Nawabi, David Liu, and Suneel Gupta, Clinical Pharmacology in Drug Development, May 4, 2021. View Page

PN-943, an Oral α4β7 Integrin Antagonist, Inhibits MAdCAM1-Mediated Proliferation and Cytokine Release from CD4+ T-Cells Independent of Trafficking

Lili Cheng, Sarayu Venkataraman, Li Zhao, Larry Lee, Tenny Tang, David Liu, Larry Mattheakis, 15th Congress of ECCO on February 12-15, 2020, Vienna, Austria.

The Oral α4β7 Integrin Specific Antagonist PN-10943 is More Effective than PTG-100 in Multiple Preclinical Studies

Larry Mattheakis, PhD, 50th Anniversary of Digestive Disease Week, May 18-21, 2019, San Diego, California, United States.

PTG-100, an Oral Gut-Restricted Peptide α4β7 Antagonist, Induces Clinical and Histologic Remission in Patients with Moderate to Severely Active Ulcerative Colitis

 William J. Sandborn, Brian Bressler, Scott Lee, Raj Bhandari, Bittoo Kanwar, Lucio Tozzi, Richard Shames, Geert D’Haens, Jean-Frederic Colombel, Stefan Schreiber, Silvio Danese, Rish K. Pai, Brian Feagan, UEG Week Vienna 2018, October 20 – 24, 2018, Vienna, Austria.

Model Based Predictions of the PTG-100 Pharmacodynamic Responses in Ulcerative Colitis Patients

Mattheakis, L., Fosser, C., Saralaya, R., Horsch, K., Rao, N., Bai, L., Zhao, L., Annamalai, T., Liu, D., 12th Congress of ECCO, February 17, 2017, Barcelona, Spain.

Safety, Pharmacokinetics and Pharmacodynamics of the Novel Oral Peptide Therapeutic PTG-100 (α4β7 Integrin Antagonist) in Normal Healthy Volunteers

Shames, R., Tozzi, L., Mattheakis, L., Annamalai, T., Bhandari, A., and Liu, D., 24th United European Gastroenterology Week, October 15-19, 2016, Vienna, Austria.

Pharmacokinetics and Pharmacodynamics Following Oral Administration Of PTG-100, a Peptide Antagonist of Integrin α4β7

Annamalai, T., Mattheakis, L., Bhandari, A., Liu, D., Zemede, G., Hadley, S., Zhao, L., Rao, N., 24th United European Gastroenterology Week, October 15-19, 2016, Vienna, Austria.

Establishing the Human Equivalent Dose for PTG-100, an Oral Peptide Antagonist of Integrin α4β7

Mattheakis, L., Zemede, G., Bai, L., Tran, V., Celino, H., Frederick, B., Zhao, L., Dogra, M., Tovera, J., Shah, S., Rao, N., Hadley, S., Bhandari, A., Annamalai, T., Patel, D., Liu, D., Digestive Disease Week, May 21-24, 2016, San Diego, United States.

PTG-100, an Oral Peptide Antagonist of Integrin α4β7 that Alters Trafficking of Gut Homing T Cells in Preclinical Animal Models

Mattheakis, L., Bhandari, A., Bai, L., Zemede, G., Tran, V., Celino, H., Frederick, B., Zhao, L., Dogra, M., Lister, H., Tovera, J., Shah, S., Annamalai, T., Patel, D., Liu, D., 2015 Advances in IBD – Crohn’s & Colitis Foundation’s Clinical & Research Conference, December 2015.